[1]
Ellison DL. Physiology of Pain. Critical Care Nursing Clinics 2017; 29(4): 397-406.
[2]
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139(2): 267-84.
[3]
Freedman M, Gehret J, Young G, Kamen L. Challenging neuropathic pain syndromes: Evaluation and evidence-based treatment: Elsevier Health Sciences; 2017.
[4]
Price DD, Verne GN, Schwartz JM. Plasticity in brain processing and modulation of pain. Prog Brain Res 2006; 157: 333-405.
[5]
Caterina PM, Beatrice PM, Lorenzo DN, et al. Nociceptor plasticity: a closer look. J Cell Physiol 2017; 233(4): 2824-38.
[6]
Ossipov M. Pain pathways: descending modulation 2009.
[7]
Carpenter K, Dickenson A. Molecular aspects of pain research. Pharmacogenomics J 2002; 2(2): 87.
[8]
Steeds CE. The anatomy and physiology of pain. Surgery-Oxford
Int Edition 2009; 27(12): 507-11.
[9]
Schaible H-G. Peripheral and central mechanisms of pain generation Analgesia. Springer 2006; pp. 3-28.
[10]
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
[11]
Świeboda P, Filip R, Prystupa A, Drozd M. Assessment of pain: types, mechanism and treatment. Pain 2013; 1: 2-7.
[12]
Sun L, Richard DY. Role of G protein-coupled receptors in inflammation. Acta Pharmacol Sin 2012; 33(3): 342.
[13]
Boddeke EW. Involvement of chemokines in pain. Eur J Pharmacol 2001; 429(1-3): 115-9.
[14]
Geppetti P, Veldhuis NA, Lieu T, Bunnett NW. G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron 2015; 88(4): 635-49.
[15]
Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002; 3(8): 655.
[16]
Okuse K. Pain signalling pathways: from cytokines to ion channels. Int J Biochem Cell Biol 2007; 39(3): 490-6.
[17]
Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med 2010; 16(11): 1248.
[18]
Das V. An introduction to pain pathways and pain “targets” Progress in molecular biology and translational science 131. Elsevier 2015; pp. 1-30.
[19]
Moore C, Gupta R, Jordt S-E, Chen Y, Liedtke WB. Regulation of pain and itch by TRP channels. Neurosci Bull 2018; 1-23.
[20]
Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nat 2000; 405(6783): 183.
[21]
Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta 2007; 1772(8): 989-1003.
[22]
Han Y, Li Y, Xiao X, et al. Formaldehyde up-regulates TRPV1 through MAPK and PI3K signaling pathways in a rat model of bone cancer pain. Neurosci Bull 2012; 28(2): 165-72.
[23]
Ching L-C, Kou YR, Shyue S-K, et al. Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res 2011; 91(3): 492-501.
[24]
Jara-Oseguera A, Simon SA, Rosenbaum T. TRPV1: on the road to pain relief. Curr Mol Pharmacol 2008; 1(3): 255-69.
[25]
Carnevale V, Rohacs T. TRPV1: a target for rational drug design. Pharmaceuticals 2016; 9(3): 52.
[26]
Johnson E, Lambert D. Receptor Mechanisms. Core Topics In
Pain.49.
[27]
Brower V. New paths to pain relief. Nat Biotechnol 2000; 18(4): 387.
[28]
Manitpisitkul P, Brandt M, Flores CM, et al. TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study. Pain Rep 2016; 1(4): e576.
[29]
Niyom S, Mama K, Gustafson D, Rezende M. Single‐and multiple dose pharmacokinetics and multiple dose pharmacodynamics of oral ABT‐116 (a TRPV 1 antagonist) in dogs. J Veterinary Pharmacol Therap 2015; 38(4): 336-43.
[30]
Hu H-Z, Gu Q, Wang C, et al. 2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem 2004; 279(34): 35741-8.
[31]
Hernández-García E, Rosenbaum T. Lipid modulation of thermal transient receptor potential channels. Curr Top Membr 2014; 74: 135-80.
[32]
Wang H, Woolf CJ. Pain TRPs. Neuron 2005; 46(1): 9-12.
[33]
Cohen MR, Huynh KW, Cawley D, Moiseenkova-Bell VY. Understanding the cellular function of TRPV2 channel through generation of specific monoclonal antibodies. PLoS One 2013; 8(12): e85392.
[34]
Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108(5): 705-15.
[35]
Voets T, Owsianik G, Nilius B. Trpm8 Transient Receptor Potential (TRP) Channels. Springer 2007; pp. 329-44.
[36]
Yin K, Zimmermann K, Vetter I, Lewis RJ. Therapeutic opportunities for targeting cold pain pathways. Biochem Pharmacol 2015; 93(2): 125-40.
[37]
Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 2009; 8(1): 55.
[38]
Andrews MD, Af Forselles K, Beaumont K, et al. Discovery of a selective TRPM8 antagonist with clinical efficacy in cold-related pain. ACS Med Chem Lett 2015; 6(4): 419-24.
[39]
Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol 2014; 171(10): 2474-507.
[40]
Fernández-Peña C, Viana F. Targeting TRPM8 for pain relief. Channels 2013; 9: 17.
[41]
Sharif-Naeini R. Contribution of mechanosensitive ion channels to somatosensation. Prog Mol Biol Transl Sci 2015; 131: 53-71.
[42]
Florez-Paz D, Bali KK, Kuner R, Gomis A. A critical role for Piezo2 channels in the mechanotransduction of mouse proprioceptive neurons. Sci Rep 2016; 6: 25923.
[43]
Ranade SS, Syeda R, Patapoutian A. Mechanically activated ion channels. Neuron 2015; 87(6): 1162-79.
[44]
Wu J, Lewis AH, Grandl J. Touch, tension, and transduction–the function and regulation of Piezo ion channels. Trends Biochem Sci 2017; 42(1): 57-71.
[45]
Borbiro I, Rohacs T. Regulation of piezo channels by cellular signaling pathways. Curr Top Membr 2017; 245-61.
[46]
Parpaite T, Coste B. Piezo channels. Curr Biol 2017; 27(7): R250-.
[47]
Gold M, Caterina M. Molecular biology of the nociceptor/transduction The Senses: A Comprehensive Reference. Elsevier Inc. 2010.
[48]
Kweon H-J, Suh B-C. Acid-sensing ion channels (ASICs): therapeutic targets for neurological diseases and their regulation. BMB Rep 2013; 46(6): 295.
[49]
Zeng W-Z, Liu D-S, Xu T-L. Acid-sensing ion channels: trafficking and pathophysiology. Channels 2014; 8(6): 481-7.
[50]
Dube G, Lehto SG, Breese NM, et al. Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels. Pain 2005; 117(1-2): 88-96.
[51]
Gu Q, Lee L-Y. Acid-sensing ion channels and pain. Pharmaceuticals 2010; 3(5): 1411-25.
[52]
Squire LR, Dronkers N, Baldo J. Encyclopedia of neuroscience. Elsevier 2009.
[53]
Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004; 240(1): 31-304.
[54]
Gourine AV, Llaudet E, Dale N, Spyer KM. ATP is a mediator of chemosensory transduction in the central nervous system. Nat 2005; 436(7047): 108.
[55]
Khakh BS. Molecular physiology of P2X receptors and ATP signalling at synapses. Nat Rev Neurosci 2001; 2(3): 165.
[56]
Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 2009; 71: 333-59.
[57]
Burnstock G. Purinergic receptors and pain. Current Pharmaceutical Des 2009; 15(15): 1717-35.
[58]
Donnelly-Roberts D, McGaraughty S, Shieh C-C, Honore P, Jarvis MF. Painful purinergic receptors. J Pharmacol Exp Ther 2008; 324(2): 409-15.
[59]
Burnstock G. Purines and purinoceptors: molecular biology overview 2010.
[60]
McGuirk S, Dolphin A. G-protein mediation in nociceptive signal transduction: an investigation into the excitatory action of bradykinin in a subpopulation of cultured rat sensory neurons. Neurosci 1992; 49(1): 117-28.
[61]
Pethő G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev 2012; 92(4): 1699-775.
[62]
Pethő G, Reeh PW. Effects of bradykinin on nociceptors. NeuroImmune Biol 2009; 8: 135-68.
[63]
Cabrini DA, Campos MM, Tratsk KS, et al. Molecular and pharmacological evidence for modulation of kinin B1 receptor expression by endogenous glucocorticoids hormones in rats. Br J Pharmacol 2001; 132(2): 567-77.
[64]
Carpenter K, Dickenson A. Peripheral and central sensitization.
Core topics in pain. 2005:29.
[65]
Cafferty W. Peripheral mechanisms. Core Topics Pain 2005; pp. 7-16.
[66]
Ikeda SR, Dunlap K. Calcium channels diversify their signaling portfolio. Nat Neurosci 2007; 10(3): 269.
[67]
Park C-G, Suh B-C. Modulation mechanisms of voltage-gated calcium channels. Curr Opin Physiol 2018; 2: 77-83.
[68]
Stevens E, Patel MBS. Barker1, GT Young2, CH Soubrane2, GJ Stephens3. Conn’s. Transl Neurosci 2016; 11.
[69]
Altier C, Zamponi GW. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 2004; 25(9): 465-70.
[70]
Channels NV-GC. Voltage-Gated Calcium Channels. Cold Spring Harb Perspect Biol 2011; 3(8): a003947.
[71]
Sprengel R. Ionotropic glutamate receptors Neuroscience in the 21st Century. Springer 2013; pp. 59-80.
[72]
Chiechio S. Modulation of chronic pain by metabotropic glutamate receptors. Adv Pharmacol 2016; 63-89.
[73]
Wang J, Goffer Y. AMPA receptors and pain—A future therapeutic intervention? Techniques in Regional Anesthesia & Pain Management 2010; 14(2): 59-64.
[74]
Dravid S, Yuan H, Traynelis S. AMPA Receptors: Molecular Biology and Pharmacology Encyclopedia of Neuroscience. Elsevier Ltd 2010.
[75]
Wang Y, Wu J, Wu Z, et al. Regulation of AMPA receptors in spinal nociception. Mol Pain 2010; 6(1): 5.
[76]
Hartmann B, Ahmadi S, Heppenstall PA, et al. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron 2004; 44(4): 637-50.
[77]
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 2013; 9(9): 948.
[78]
Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003; 97(4): 1108-16.
[79]
Iacobucci GJ, Popescu GK. NMDA receptors: linking physiological output to biophysical operation. Nat Rev Neurosci 2017; 18(4): 236.
[80]
Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nat 1997; 386(6626): 721.
[81]
Zito K, Scheuss V. NMDA receptor function and physiological modulation. In: Encyclopedia of Neuroscience. 2009; p. pp.1157-1164.
[82]
Chen J, Li L, Chen S-R, et al. The α2δ-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Reports 2018; 22(9): 2307-21.
[83]
Lee C-H, Lü W, Michel JC, et al. NMDA receptor structures reveal subunit arrangement and pore architecture. Nat 2014; 511(7508): 191.
[84]
Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000; 19(1): 2-6.
[85]
Palazzo E, Marabese I, Novellis V, Rossi F, Maione S. Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond. Eur J Neurosci 2014; 39(3): 444-54.
[86]
Grueter B, Winder D. Metabotropic glutamate receptors (mGluRs). Functions 2009.
[87]
C Montana M. W Gereau R. Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharmaceutical Biotechnol 2011; 12(10): 1681-8.
[88]
Carlton SM, Neugebauer V. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin Ther Targets 2002; 6(3): 349-61.
[89]
Goudet C, Magnaghi V, Landry M, et al. Metabotropic receptors for glutamate and GABA in pain. Brain Res Brain Res Rev 2009; 60(1): 43-56.
[90]
Karim F, Bhave G, Gereau IVR. Metabotropic glutamate receptors on peripheral sensory neuron terminals as targets for the development of novel analgesics. Nature Publishing Group 2001.
[91]
De Blasi A, Conn PJ, Pin J-P, Nicoletti F. Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol Sci 2001; 22(3): 114-20.
[92]
Trafton JA, Basbaum AI. The contribution of spinal cord neurokinin-1 receptor signaling to pain. J Pain 2000; 1(3): 57-65.
[93]
Jimenez-Andrade J, Mantyh P. Neuropeptides Internalization Encyclopedia of Neuroscience. Elsevier Ltd 2010.
[94]
Schank JR, Heilig M. Substance P and the Neurokinin-1 Receptor: The New CRF International review of neurobiology 136. Elsevier 2017; pp. 151-75.
[95]
Gautam M, Prasoon P, Kumar R, et al. Role of neurokinin type 1 receptor in nociception at the periphery and the spinal level in the rat. Spinal Cord 2016; 54(3): 172.
[96]
Goldsmith L, Kwatra M. Tachykinin/Substance P/Neurokinin-1
Receptors. 2013.
[97]
Pintér E, Pozsgai G, Hajna Z, Helyes Z, Szolcsányi J. Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol 2014; 77(1): 5-20.
[98]
Kenchappa R, Carter B. Neurotrophin Receptor Signaling 2013.
[99]
Sanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Clin Pharmacol 2004; 141(8): 1303-12.
[100]
Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine. Pain 2017; 158(4): 543.
[101]
Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 2017; 18(1): 34.
[102]
Ma W, Chabot J-G, Quirion R. Calcitonin Gene-Related Peptide (CGRP) and Receptors. 2009.
[103]
Benemei S, Nicoletti P, Capone JG, Geppetti P. CGRP receptors in the control of pain and inflammation. Curr Opin Pharmacol 2009; 9(1): 9-14.
[104]
Russell F, King R, Smillie S-J, Kodji X, Brain S. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014; 94(4): 1099-142.
[105]
Chan HS, McCarthy D, Li J, Palczewski K, Yuan S. Designing safer analgesics via μ-opioid receptor pathways. Trends Pharmacol Sci 2017; 38(11): 1016-37.
[106]
McDonald J, Lambert D. Opioid receptors. Continuing Education in Anaesthesia Critical Care Pain 2005; 5(1): 22-5.
[107]
Rice F, Albrecht P. The senses: a comprehensive reference. Basbaum, AI 2008; 1-32.
[108]
Waldhoer M, Bartlett SE, Whistler JL. Opioid Receptors. Annu Rev Biochem 2004; 73: 953-90.
[109]
François A, Low SA, Sypek EI, et al. A brainstem-spinal cord inhibitory circuit for mechanical pain modulation by GABA and enkephalins. Neuron 2017; 93(4): 822-39. e6.
[110]
Kieffer B. Opioid peptides and receptors. Elsevier Ltd 2009.
[111]
Nagi K, Piñeyro G. Regulation of opioid receptor signalling: implications for the development of analgesic tolerance. Mol Brain 2011; 4(1): 25.
[112]
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology: J Am Society Anesthesiol 2011; 115(6): 1363-81.
[113]
Hieble J. Adrenergic receptors 2009.
[114]
Bylund DB. Adrenergic receptors 2004.
[115]
Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog 2015; 62(1): 31-8.
[116]
Carroll I, Mackey S, Gaeta R. editors. The role of adrenergic receptors
and pain: The good, the bad, and the unknown. Seminars in
Anesthesia, Perioperative Medicine and Pain; 2007: Elsevier.
[117]
Fairbanks CA, Stone LS, Wilcox GL. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol Ther 2009; 123(2): 224-38.
[118]
Nguyen V, Tiemann D, Park E, Salehi A. Alpha-2 agonists. Anesthesiol Clin 2017; 35(2): 233-45.
[119]
Bardin L. The complex role of serotonin and 5-HT receptors in
chronic pain. Behav Pharmacol 2011; 22(5 and 6): 390-404.
[120]
Loyd DR, Henry MA, Hargreaves KM. editors. Serotonergic neuromodulation
of peripheral nociceptors. Seminars in cell & developmental
biology; 2013: Elsevier.
[121]
Ramage A. Serotonin (5-hydroxtryptamine; 5-HT): neurotransmission
and neuromodulation. Academic Press; 2009.
[122]
Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms—implications of 5-HT7 and other 5-HT receptor types. Eur J Pharmacol 2013; 716(1-3): 8-16.
[123]
Sommer C. Serotonin in pain and analgesia. Mol Neurobiol 2004; 30(2): 117-25.
[124]
Gresch PJ. Serotonin Receptor Signaling 2013.
[125]
Turner JH, Gelasco AK, Ayiku HB, Coaxum SD, Arthur JM, Garnovskaya MN. 5-HT receptor signal transduction pathways The serotonin receptors. Springer 2006; pp. 143-206.
[126]
Millan MJ. editor Serotonin (5-HT) and pain: a reappraisal of its
role in the light of receptor multiplicity. Seminars in Neuroscience;
1995: Elsevier.
[127]
De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53(10): 1520-35.
[128]
Lutz B, Marsicano G. Endocannabinoid role in synaptic plasticity and learning 2009.
[129]
Chiou L-C, Hu SS-J, Ho Y-C. Targeting the cannabinoid system for pain relief? Acta Anaesthesiol Taiwan 2013; 51(4): 161-70.
[130]
Piomelli D. Endocannabinoids. 2013.
[131]
Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 2006; 30(S1): S13.
[132]
Brooks JW, Farquhar‐Smith WP. Cannabinoids and pain. Bja Cepd Rev 2003; 3(6): 175-8.
[133]
Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4(3): 239-57.
[134]
Lu D, Potter D. Cannabinoids and the cannabinoid receptors: An overview Handbook of Cannabis and Related Pathologies. Elsevier 2017; pp. 553-63.
[135]
Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 2009; 30(2): 79-84.
[136]
Piomelli D, Giuffrida A, Calignano A. de Fonseca FRg. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21(6): 218-24.
[137]
Zhuo M. Ionotropic glutamate receptors contribute to pain transmission and chronic pain. Neuropharmacology 2017; 112: 228-34.
[138]
Christian K, Song H, Ming G-L. Biochemistry of Neurogenesis 2013.
[139]
Sałat K, Jakubowska A, Kulig K. Zucapsaicin for the treatment of neuropathic pain. Expert Opin Investig Drugs 2014; 23(10): 1433-40.
[140]
Lee J, Kim B-H, Yu K-S, et al. A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers. Drug Des Devel Ther 2017; 11: 1301.
